Curcumin,Placebo

5 trials

Sponsors

Rheumatic Disease Unit, Department of Medicine, Faculty of medicine, prince of songkla university, Faculty of Medicine, Chiang Mai University, Phramongkutklao Hospital

Conditions

&#45Active rheumatoid arthritis patients Rheumatoid arthritisMetabolic syndrome patients with mild cognitive impairment metabolic syndrome mild cognitive impairment cognitive dysfunction mild neurocognitive disordermoderate-severe premenstrual syndromes from PSST Questionnaire PMS Premenstrual syndromes Curcuminpatients with cancer anorexic cachexia. Advanced solid cancers, cancer anorexic cachexia.

Phase 2

Curcumin in patients cancer cachexic anorexia

Active, not recruitingTCTR20220521003

Phramongkutklao Hospitalpatients with cancer anorexic cachexia. Advanced solid cancers, cancer anorexic cachexia.

Start: 2020-10-09Target: 60Updated: 2026-08-03

Phase 3

The efficacy and safety of curcumin for pain relief in chronic kidney disease patients with knee osteoarthritis

Active, not recruitingTCTR20191106006

Faculty of medicine, prince of songkla university&#45

Start: 2019-10-01Updated: 2026-08-03

Phase 4

A randomized double-blind controlled trial to assess the efficacy and safety of curcumin versus placebo in active rheumatoid arthritis patients

RecruitingTCTR20181115012

Rheumatic Disease Unit, Department of MedicineActive rheumatoid arthritis patients Rheumatoid arthritis

Start: 2018-02-01Target: 34Updated: 2026-08-03

Curcumin with reducing symptoms in premenstrual women in Thailand

RecruitingTCTR20210219006

moderate-severe premenstrual syndromes from PSST Questionnaire PMS Premenstrual syndromes Curcumin

Start: 2021-02-01Target: 36Updated: 2026-08-03

Effects of Curcumin on Improving Mild Cognitive Impairment in Adults and Elderly Subjects with Metabolic Syndrome: A Randomized Controlled Trial

Active, not recruitingTCTR20210304001

Faculty of Medicine, Chiang Mai UniversityMetabolic syndrome patients with mild cognitive impairment metabolic syndrome mild cognitive impairment cognitive dysfunction mild neurocognitive disorder

Start: 2021-05-01Target: 150Updated: 2026-08-03